SkyOak Wealth LLC Acquires 13,027 Shares of Lantheus Holdings, Inc. $LNTH

SkyOak Wealth LLC grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,249 shares of the medical equipment provider’s stock after acquiring an additional 13,027 shares during the period. SkyOak Wealth LLC’s holdings in Lantheus were worth $2,988,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Focus Financial Network Inc. boosted its holdings in Lantheus by 4.0% in the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock worth $293,000 after purchasing an additional 136 shares in the last quarter. Park Avenue Securities LLC lifted its position in shares of Lantheus by 6.7% in the second quarter. Park Avenue Securities LLC now owns 2,841 shares of the medical equipment provider’s stock worth $233,000 after buying an additional 179 shares during the last quarter. Moody National Bank Trust Division lifted its position in shares of Lantheus by 1.2% in the second quarter. Moody National Bank Trust Division now owns 15,095 shares of the medical equipment provider’s stock worth $1,236,000 after buying an additional 185 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Lantheus by 20.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock worth $103,000 after acquiring an additional 212 shares in the last quarter. Finally, First National Advisers LLC increased its holdings in shares of Lantheus by 0.8% during the 2nd quarter. First National Advisers LLC now owns 27,995 shares of the medical equipment provider’s stock valued at $2,292,000 after acquiring an additional 213 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ:LNTH opened at $69.68 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29. The company has a fifty day moving average price of $60.44 and a 200 day moving average price of $61.55. The stock has a market cap of $4.62 billion, a P/E ratio of 29.28 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Truist Financial raised their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Mizuho lifted their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. B. Riley lowered their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. Finally, The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.